Journal of Young Pharmacists logo
Article

A Study on Drug-Drug Interaction of Esomeprazole and Anti-Diabetic Drugs

1, 2★, 1, 1, 1★ Corresponding author

  1. 1Department of Pharmacology, S.C.S. College of Pharmacy, Harapanahalli - 583131, Karnataka, INDIA.
  2. 2College of Clinical Pharmacy, King Faisal University, Alahsa, KINGDOM OF SAUDI ARABIA.

CORRESPONDENCE

Setty RS

College of Clinical Pharmacy, King Faisal University, Alahsa, KINGDOM OF SAUDI ARABIA.

rssiddamsetty@rediffmail.com

Volume 2, Issue 4 · pp. 424-427 · 2010 · DOI: 10.4103/0975-1483.71624

ABSTRACT

Drug–drug interaction between esomeprazole at therapeutic and higher doses and sulfonylureas was studied. Sulfonylureas (tolbutamide 40 mg/kg and glibenclamide 40 μg/kg) were administered and the time to onset of hypoglycemia, the duration of the hypoglycemia, and the peak hypoglycemia were determined. Esomeprazole (1.8 mg/kg, 3.6 mg/kg, and 30 mg/kg) was administered for 8 days and its influence on sulfonylurea-induced hypoglycemia was studied. Therapeutic doses of esomeprazole, i.e., 1.8 mg/kg and 3.6 mg/kg dose did not influence the hypoglycemia induced by sulfonylureas. However, a higher dose, i.e., 30 mg/kg, did significantly enhance the duration of hypoglycemia and the peak hypolgycemia. Esomeprazole (30 mg/kg) by itself did not reduce the blood glucose levels; therefore, a pharmacodynamic type of drug interaction can be ruled out. Similarly, a pharmacokinetic type of drug interaction may be ruled out at therapeutic doses. The CYP isoenzyme system involved in the metabolism of sulfonylureas are not very sensitive to esomeprazole and the dose and frequency of administration of sulfonylurea need not be readjusted when they are used concomitantly with esomeprazole (at therapeutic doses).

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    VKM, S., RS, S., MM, S., TM, J., & SV, R. (2010). A Study on Drug-Drug Interaction of Esomeprazole and Anti-Diabetic Drugs. Journal of Young Pharmacists, 2(4), 424-427. https://doi.org/10.4103/0975-1483.71624

    Copyright and licence

    © 2010 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0